Preclinical and First-in-Human Study of Carbonic Anhydrase IX-Targeting Theranostic Pair, [68Ga]Ga/[177Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma [0.03%]
一种用于治疗和诊断的放射配对体[NYM096-68Ga/Ga-NYM096]在透明细胞肾癌中的临床前及首次人体研究
Jingnan Wang,Xinchun Yan,Meixi Liu et al.
Jingnan Wang et al.
Small-molecule PET tracers targeting carbonic anhydrase IX (CAIX) have recently been developed for patients with clear cell renal cell carcinoma (ccRCC). Here, we report the preclinical results and first-in-human study of a CAIX-targeting t...
Circulating Tumor DNA Genomic Profiling in 223Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study [0.03%]
卡倍 Shrine 治疗的转移性去势抵抗性前列腺癌患者循环肿瘤DNA基因组分析：KYUCOG-1901研究
Masaki Shiota,Maki Fujiwara,Takayuki Sumiyoshi et al.
Masaki Shiota et al.
Circulating tumor DNA (ctDNA) testing has emerged as a cancer precision medicine approach. We investigated the genomic landscape and clinical utility of ctDNA in patients receiving 223Ra dichloride for bone metastatic castration-resistant p...
Dynamic Total-Body PET Imaging Unfolds [11C]Choline Kinetics and Dosimetry in Primary Hyperparathyroidism [0.03%]
动态全身PET成像解析原发性甲状旁腺功能亢进症的碳11胆碱动力学和剂量学
Irene Brusa,Miriam Santoro,Daniele Dall&#x;Olio et al.
Irene Brusa et al.
This study investigated the biodistribution profile, kinetic constants, and dosimetry of [11C]choline in patients with primary hyperparathyroidism (pHPT) using total-body dynamic PET (dPET) imaging, to establish a baseline and standard refe...
ICOS-Targeted Peptide Imaging Informs Therapeutic Response of STING Agonist in Lung Adenocarcinoma [0.03%]
利用ICOS靶向肽对肺腺癌STING激动剂治疗反应进行成像分析
Shao Duan,Boyu Tan,Yuqiang Mao et al.
Shao Duan et al.
The innovation of cancer immunotherapy is improving clinical theranostics for lung cancer. Given the variation of therapeutic effects among patients, there is an urgent need to develop novel tools for precisely evaluating immune responses. ...
Prognostic Value of PSMA PET-Derived Tumor Burden Stratification in Metastatic Hormone-Sensitive Prostate Cancer [0.03%]
PSMA显像导癌负荷分层在转移性雄激素敏感性前列腺癌中的预后价值分析
Lena M Unterrainer,Honest Ndlovu,Thomas A Hope et al.
Lena M Unterrainer et al.
The addition of prostate-specific membrane antigen (PSMA) PET to conventional imaging (CI) leads to both downstaging and upstaging in a substantial proportion of patients with metastatic hormone-sensitive prostate cancer (mHSPC) when applyi...
Prospective Head-to-Head Comparison of Fibroblast Imaging with [68Ga]Ga-FAPI-46 PET/CT and [18F]FDG PET/CT in Unclear Hepatic Lesions [0.03%]
[68Ga]Ga-FAPI-46 PET/CT和[18F]FDG PET/CT在肝结节病变中鉴别纤维板层样肝细胞癌的前景：一项头对头比较研究
Susanne Stanzel,Tina Nazerani-Zemann,Friedrich Weitzer et al.
Susanne Stanzel et al.
This study aimed to compare the performance of 68Ga-labeled fibroblast activation protein inhibitor 46 ([68Ga]Ga-FAPI-46) PET/CT and [18F]FDG PET/CT in characterizing unclear hepatic lesions. Methods: We prospectively evaluated 59 patients ...
Utility of PSMA PET/CT After an Initial Negative Scan: Results from a Prospective Multicenter PSMA PET Registry [0.03%]
PSMA PET/CT前瞻性多中心登记处的初步价值：初始扫描结果为阴性后的PSMA PET/CT的效果
Ur Metser,Glenn Bauman,Mohammed Rashid et al.
Ur Metser et al.
There is a paucity of data on the utility of a second prostate-specific membrane antigen (PSMA) PET/CT scan after an initial negative scan in patients with recurrent prostate cancer. The purpose of this study was to assess the utility of a ...
A Novel CD147-Targeting Nanobody for Immuno-PET Imaging of Liver Cancer [0.03%]
一种用于肝癌免疫PET成像的新型CD147靶向纳米抗体
Divya M Nambiar,Thomas J Esparza,Woonghee Lee et al.
Divya M Nambiar et al.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with a 5-y survival rate of approximately 20%. Many patients undergo locoregional therapy, and distinguishing viable tumor from treated necrotic tissue pres...
Patterns of Progression After Peptide Receptor Radiopharmaceutical Therapy [0.03%]
肽受体放射性配体治疗后的疾病进展情况分析
Moein Moradpour,Abuzar Moradi Tochayi,Sina Houshmand et al.
Moein Moradpour et al.
[177Lu]Lu-DOTATATE has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). It is often thought that NET progression may result in somatostatin receptor (SSTR)-negative disease because of the elimination o...
Brain Metabolic Activity Measured by [18F]FDG PET/CT Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer [0.03%]
[18F]FDG正电子发射断层显像/计算机体层成像测定的脑代谢活性对晚期非小细胞肺癌患者的生存期具有预后价值
Julie Auriac,Ghada Lemoudda,Narinée Hovhannisyan-Baghdasarian et al.
Julie Auriac et al.
[18F]FDG PET/CT images play a key role in the management of patients with non-small cell lung cancer (NSCLC). In these scans, the focus is on detected tumors and their characteristics, neglecting information from other organs or tissues. We...